GTO ID | GTC3210 |
Trial ID | NCT05580796 |
Disease | Solid Tumor |
Altered gene | TAA |
Therapeutic/Target gene | Target gene |
Therapy | TCR-T cell |
Treatment | KSH01 TCR-T cells |
HLA | HLA-A*02 |
Phase | Phase1 |
Recruitment status | Recruiting |
Title | Investigator Initiated Clinical Trial on the Tolerance, Safety and Preliminary Efficacy of KSH01-TCRT Injection in Solid Tumor Subjects |
Year | 2022 |
Country | China |
Company sponsor | TCRx Therapeutics Co.Ltd |
Other ID(s) | KSH01-R02-101 |
Cohort 1 | |||||||||
|